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Background: Myxoid liposarcoma occurs in middle age, and is characterized by extrapulmonary metastasis,
including bone metastasis. Bone scans and [18F]-2-fluoro-2-deoxy-D-glucose-positron emission tomography
(FDG-PET) are widely used for assessment of tumor extension, including vertebral metastasis. However, both
methods have a low positive rate with regard to vertebral metastasis arising from myxoid liposarcoma. This is
particularly true for bone scans for intramedullary lesions that have no cortical involvement.
Case presentation: We present the case of a 53-year-old male with myxoid liposarcoma in the leg. He had been
treated for multiple metastases over a ten-year period, and was experiencing back pain due to a pathological
fracture in the second lumbar vertebra (L2). Magnetic resonance imaging of all the vertebrae showed abnormal
signal intensity suggestive of metastasis in eight vertebrae, and revealed extraskeletal extension in three vertebrae.
Bone scans and FDG-PET were negative except for the L2 fracture which was indicated on a bone scan.
Conclusions: Both bone scans and FDG-PET can be negative in cases of vertebral metastasis that arise from
myxoid liposarcoma, even when extraskeletal extensions are present. Similarly, even a fractured vertebra may not
always be visible on FDG-PET.
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Myxoid liposarcoma is one of the subtypes of liposar-
coma. This subtype typically peaks in the fourth and
fifth decades of life [1]. Myxoid liposarcoma is com-
monly associated with TLS-CHOP fusion transcript
[2,3]. In contrast to other soft-tissue sarcomas that show
a tendency for metastasis to the lung, myxoid liposar-
coma has a propensity to spread to extrapulmonary sites,
including bone [4,5]. The frequency of bone metastasis
arising from myxoid liposarcoma has been reported to
be 14% [1] and 17% [6].
Bone scans and [18F]-2-fluoro-2-deoxy-D-glucose-
positron emission tomography (FDG-PET) are useful for* Correspondence: akio@med.kyushu-u.ac.jp
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reproduction in any medium, provided the ordetecting distant metastases from various tumors. Bone
scans are sensitive to unusual bone remodeling activity
because radioactive material is taken up by osteoblasts.
On the other hand, FDG-PET can be evaluated using the
standardized uptake value (SUV). An increased SUV
reflects increased glucose metabolism as a result of vari-
ous factors such as increased glucose transporters, high
levels of hexokinase and a reduction in glucose-6-
phosphatase [7,8]. FDG-PET has been reported to be
useful for the diagnosis of soft-tissue tumors [9].
Bone scans and FDG-PET have been reported to lack
sufficient sensitivity for the detection of vertebral metas-
tases arising from myxoid liposarcoma. Among vertebral
metastases detected by magnetic resonance imaging
(MRI), positive rates with bone scans and FDG-PET
have been reported to be 16% and 14%, respectively, in a
number of vertebrae [6]. It also has been reported that
the positive rate with bone scans for vertebral metastasisral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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lesions that have no cortical involvement [10]. In the
current study, we report the case of a man with myxoid
liposarcoma with multiple vertebral metastases. Al-
though some of the metastatic vertebrae had extended
extraskeletally, all the metastatic vertebral lesions were
negative on bone scans and FDG-PET, except for the
fractured vertebra, which was visible on a bone scan.
Case presentation
A 43-year-old man with a tumor in his left leg was re-
ferred to our institute. The diagnosis was myxoid liposar-
coma based upon biopsy findings. Radiation and
chemotherapy were administered. Consequent wide re-
section with the surrounding normal tissue was per-
formed. Two years after the initial surgery, when the
patient was 45 years of age, metastasis appeared in the
right neck region and the retroperitoneum, and resection
of these lesions was performed. Seven years after the ini-
tial surgery, when the patient was 50 years of age, lung
metastasis was found and resection was performed. Eight
years after the initial surgery, when the patient was 51
years of age, recurrence was found in the thigh and
involved the major vessels. Amputation at the thigh was
carried out. Histological diagnosis of myxoid liposarcoma
was confirmed in each of the resected materials. Chemo-
therapy was performed after every resection of metastatic
and recurrent lesions. Ten years after the initial oper-
ation, at 53 years of age, the patient experienced back
pain. Plain radiographs showed a compression type
fracture in the second lumbar vertebra. MRI of all the
vertebrae showed abnormally high signal intensity on
T2-imaging with fat suppression in eight vertebrae: the
fifth cervical vertebra (C5), the seventh, tenth, eleventh
and twelfth thoracic vertebrae (T7, T10, T11 and T12),
the second and fourth lumbar vertebrae (L2 and L4),
and the second sacral vertebra (S2). High signal inten-
sity on the MRI was seen throughout the entireFigure 1 Magnetic resonance imaging shows high signal intensity on
Pathological fracture is evident in the second vertebra. Extraskeletal extensi
and second sacral vertebra.vertebral body in L2 accompanied by deformity, sug-
gestive of a pathological fracture. Extraskeletal exten-
sion of the lesion was seen in the T12, L2 and S2
vertebrae (Figure 1). Bone scans showed negative find-
ings except for the L2 fracture. FDG-PET was negative
for all of the vertebrae, including the fractured L2 ver-
tebra (Figure 2). These examinations of bone scans and
FDG-PET were performed within one month after the
MRI examination. With a diagnosis of vertebral metas-
tasis arising from myxoid liposarcoma, radiation and
chemotherapy were administered. The patient was
informed that data from his case would be submitted
for publication, and his consent was obtained.
Conclusions
Myxoid liposarcoma is characteristic in giving rise to extra-
pulmonary metastasis, such as to the retroperitoneum, the
axilla and the mesentery, while other soft-tissue sarco-
mas demonstrate a tendency to metastasize to the lung
[3,11,12]. The overall rate of metastasis in myxoid lipo-
sarcoma has been reported to be one-third [2,6]. The
frequency of bone metastasis arising from myxoid lipo-
sarcoma has been reported to be 14% [1] and 17% [6].
The actual frequency of vertebral metastasis of myxoid
liposarcoma is not clear, since a low metastatic rate of
4.3% has also been reported [13].
Bone scans are known to be more sensitive than plain
radiographs for detecting bone metastasis [13]. A low
positive rate with bone scans has been reported for ver-
tebral metastasis arising from myxoid liposarcoma. In a
previous report, bone scans revealed three out of nine
cases (33%) and five out of 32 vertebrae (16%), based
upon known metastasis as shown on MRI [6]. As for the
sensitivity of bone scans, a lower positive rate for meta-
static bone tumors in various malignancies has been
reported in cases of intramedullary lesions without cor-
tical involvement [10]. In the current report, although
the vertebral lesions had extended extraskeletally ina T2-image with fat suppression in multiple vertebrae.
on is visible in the eleventh thoracic vertebra, second lumbar vertebra
Figure 2 Positive findings can be seen on the bone scan in the fractured second lumbar vertebra (L2) (A). Coronal section (B) and axial
sections of twelfth thoracic vertebra (T12) (C), L1 (D), L2 (E) and the first sacral vertebra (S1) (F) in FDG-PET are shown. There are no obvious
differences between FDG uptake in metastatic vertebrae of T12 (C), L2 (E), and the non-metastatic vertebrae of L1 (D) and S1 (F). FDG-PET,
[18F]-2-fluoro-2-deoxy-D-glucose-positron emission tomography.
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tive in all cases except for the one vertebra that was frac-
tured. The reason for this low positive rate in cases of
myxoid liposarcoma is still not clear. In certain condi-
tions such as myeloma or lesions confined to the mar-
row, bone scans have shown low sensitivity [14]. It has
been suggested that hematogenously seeded intramedul-
lary metastasis produces marrow replacement lesions
without destroying the bone structure [15]. Moreover,
myeloma cells promote osteoclast activity but inhibit
osteoblast differentiation, which may explain the nega-
tivity of bone scans [16].
An increased uptake of FDG-PET in cells reflects
increased glucose metabolism [7,8], and has been used
to evaluate the extent of disease. As for bone and soft-
tissue tumors, it has been reported that malignant
tumors tend to have a higher SUV than benign tumors
[9]. A low positive rate of FDG-PET has been reported
in cases of vertebral metastasis of myxoid liposarcoma.
In a previous report, FDG-PET revealed two out of six
cases (33%), and four out of 29 vertebrae (14%), based
upon known metastasis as shown on MRI [6]. The rea-
son FDG-PET has a lower positive rate in cases of verte-
bral metastasis of myxoid liposarcoma is not clear. It hasbeen assumed that the myxoid stroma in myxoid liposar-
coma may prevent the labeled glucose from reaching
cells in a sufficient quantity to be detected by the scan-
ner [6]. Interestingly, in the current case, SUV was still
negative in FDG-PET even in the fractured vertebra,
whereas positive results were seen on the bone scan. A
fracture site is usually positive on FDG-PET. The dis-
crepancy between the results of the FDG-PET and the
bone scan for the fractured vertebra could be associated
with a specific biological mechanism, such as mild inhib-
ition of the healing reaction at the fracture site.
In summary, a case of myxoid liposarcoma with mul-
tiple vertebral metastases is reported. Bone scans and
FDG-PET were negative, even for lesions with extraske-
letal extension, except for the L2 fracture which was vis-
ible on a bone scan. Bone scans and FDG-PET can thus
be negative in cases of multiple vertebral metastases of
myxoid liposarcoma, and even a fractured vertebra may
not be visible on FDG-PET.
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